Sanches TR, Volpini RA, Massola Shimizu MH, de Bragança AC, Oshiro-Monreal F, Seguro AC, Andrade L. Sildenafil reduces polyuria in rats with lithium-induced NDI. Am J Physiol Renal Physiol 302: F216 -F225, 2012. First published October 12, 2011 doi:10.1152/ajprenal.00439.2010.-Lithium (Li)-treated patients often develop urinary concentrating defect and polyuria, a condition known as nephrogenic diabetes insipidus (NDI). In a rat model of Li-induced NDI, we studied the effect that sildenafil (Sil), a phosphodiesterase 5 (PDE5) inhibitor, has on renal expression of aquaporin-2 (AQP2), urea transporter UT-A1, Na ϩ /H ϩ exchanger 3 (NHE3), Na ϩ -K ϩ -2Cl Ϫ cotransporter (NKCC2), epithelial Na channel (ENaC; ␣-, ␤-, and ␥-subunits), endothelial nitric oxide synthase (eNOS), and inducible nitric oxide synthase. We also evaluated cGMP levels in medullary collecting duct cells in suspension. For 4 wk, Wistar rats received Li (40 mmol/kg food) or no treatment (control), some receiving, in weeks 2-4, Sil (200 mg/kg food) or Li and Sil (LiϩSil). In LiϩSil rats, urine output and free water clearance were markedly lower, whereas urinary osmolality was higher, than in Li rats. The cGMP levels in the suspensions of medullary collecting duct cells were markedly higher in the LiϩSil and Sil groups than in the control and Li groups. Semiquantitative immunoblotting revealed the following: in LiϩSil rats, AQP2 expression was partially normalized, whereas that of UT-A1, ␥-ENaC, and eNOS was completely normalized; and expression of NKCC2 and NHE3 was significantly higher in Li rats than in controls. Inulin clearance was normal in all groups. Mean arterial pressure and plasma arginine vasopressin did not differ among the groups. Sil completely reversed the Li-induced increase in renal vascular resistance. We conclude that, in experimental Liinduced NDI, Sil reduces polyuria, increases urinary osmolality, and decreases free water clearance via upregulation of renal AQP2 and UT-A1.
LITHIUM (Li) has been widely used as a pharmacological agent in psychiatric therapy and is the established drug of choice for treating bipolar affective disorders (20, 21, 29, 31) . It is eliminated primarily through renal excretion and competes with the Na-K-2Cl cotransporter (NKCC2) and the epithelial sodium channel (ENaC) (12, 13, 39) . In addition, Li is transported by Na-K-ATPase (12, 13, 39) . Approximately 60% of the filtered load of Li is reabsorbed in the proximal tubule, whereas 20% is reabsorbed in the thick ascending limb, connecting tubule, and cortical collecting duct (12, 13) . Nephrogenic diabetes insipidus (NDI), increased urinary excretion of sodium (UVNa), and distal renal tubular acidosis have all been associated with Li treatment (16, 17, 22, 31) . In particular, Li-induced NDI is associated with dysregulation of aquaporin-2 (AQP2) and ENaC in the collecting duct (20, 22, 23, 26, 41) . Furthermore, reduced urine concentrating ability has been shown to accompany decreased expression of the inner medullary urea transporter UT-A1 in Li-treated rats (2, 18) .
The most widely understood pathway leading to AQP2 membrane accumulation is arginine vasopressin (AVP) type 2 receptor stimulation of adenylyl cyclase, cAMP-mediated activation of PKA, and AQP2 phosphorylation, the last being necessary for AVP-stimulated membrane accumulation of AQP2 (6, 7, 15, 28) . Bouley et al. (4) showed that acute elevation of intracellular cGMP levels induced by nitric oxide (NO), L-arginine, or atrial natriuretic peptide also leads to AQP2 membrane insertion in transfected epithelial cells, as well as in principal cells, in the renal collecting duct. In another study (5) , those same authors demonstrated that this cGMPmediated AQP2 trafficking can occur even in the absence of elevated intracellular cAMP levels and is therefore independent of stimulation of the AVP type 2 receptor signaling pathway. The authors demonstrated elevated intracellular cGMP levels and greater plasma membrane accumulation of AQP2 in LLC-AQP2 cells exposed to sildenafil citrate (Sil; Viagra), a phosphodiesterase 5 (PDE5) inhibitor (5) . These data suggest that cGMP-specific PDE inhibitors induce activation of a parallel cGMP-mediated signal transduction pathway, thereby allowing AQP2 membrane insertion to occur without activation of the AVP type 2 receptor (4, 5) . This indicates that pharmacological activation of AVP-independent cGMP signaling pathways can aid in the treatment of some forms of NDI.
We hypothesized that Sil increases AQP2 expression and would thus be useful in treating Li-induced NDI. Therefore, we investigated the effects of Sil on renal expression of UT-A1, AQP2, Na ϩ /H ϩ exchanger 3 (NHE3), NKCC2, and ENaC (␣-, ␤-,and ␥-subunits) in rats with Li-induced NDI.
METHODS

Animals and Experimental Protocol
Male Wistar rats, weighing 150 -250 g, were obtained from the animal facility of the University of São Paulo School of Medicine. Experimental NDI was induced by administration of Li, and the rats were then treated or not with Sil. The experimental protocol was approved by the Ethics Committee of the University of São Paulo School of Medicine. During the 4-wk study period, all animals were fed standard rat chow, with a fixed concentration of sodium chloride (0.5%), and were given ad libitum access to tap water. The rats were divided into four groups: control (n ϭ 5), fed standard rat chow for 4 wk; Sil (n ϭ 5), fed standard rat chow for 4 wk plus Sil (200 mg/kg food) for the last 3 wk of that period; Li (n ϭ 9), fed standard rat chow plus Li (40 mmol/kg food) for 4 wk; and LiϩSil (n ϭ 8), fed standard rat chow plus Li (40 mmol/kg food) for 4 wk plus Sil (200 mg/kg food) for the last 3 wk of that period.
We performed a second set of experiments to further measure mean arterial pressure (MAP) and renal vesicle resistance [RVR; via renal blood flow (RBF)], as well as to determine plasma AVP levels.
To determine whether, in Li-treated animals, a higher dose of Sil would have different effects than did the standard dose (200 mg/kg food), we also evaluated a group of rats receiving Li and a higher dose of Sil, the LiϩSil-hi group (n ϭ 5), which comprised rats fed standard rat chow plus Li (40 mmol/kg food) for 4 wk and receiving Sil (400 mg/kg food) for the last 3 wk of that period. Initial tests (urine output, urinary osmolality, and water intake) showed no significant differences between the LiϩSil and LiϩSil-hi groups. Therefore, the remaining parameters were not determined in the LiϩSil-hi group.
Metabolic cage studies. Rats were housed one per cage, maintained on a 12:12-h light-dark cycle, and acclimated to the housing conditions for 2 days before the experimental procedures. They were then placed in metabolic cages to collect 24-h urine samples, at baseline and at the end of weeks 1, 2, 3, and 4. At the end of week 4, rats were anesthetized with thiopental sodium (50 mg/kg body wt). To measure MAP, the right or left carotid artery was catheterized with a PE-50 catheter. A median incision was made to measure RBF; the left renal pedicle was carefully dissected, and the renal artery was isolated with care to avoid disturbing the renal nerves. An electromagnetic flow probe was placed around the exposed renal artery, and RBF was measured with an electromagnetic flowmeter (T 106 XM; Transonic Systems, Bethesda, MD). Whole blood was then collected from the carotid artery, and the kidneys were immediately removed. The rats were then euthanized with an overdose of anesthesia. Kidneys were dissected to obtain cortex and medulla samples. Cortex and medulla tissue samples were frozen in liquid nitrogen and stored at Ϫ80°C.
To calculate RVR, we divided MAP by RBF (results expressed as mmHg·ml Ϫ1 ·min). Clearance studies. To study renal function, inulin clearance studies were conducted, additional groups of rats being submitted to the 4-wk study protocol described above: control (n ϭ 5); Sil (n ϭ 4); Li (n ϭ 4); and LiϩSil (n ϭ 5).
Before the performance of the clearance studies, each animal was anesthetized intraperitoneally with 50 mg/kg body wt of thiopental sodium. The trachea was cannulated with a PE-240 catheter, and spontaneous breathing was maintained. To control MAP and allow blood sampling, a PE-60 catheter was inserted into the right carotid artery. To collect urine samples, a suprapubic incision was made, and the urinary bladder was cannulated with a PE-240 catheter. Following the surgical procedure, a loading dose of inulin (100 mg/kg body wt) was administered through the jugular vein. We started and maintained constant infusion of inulin (10 mg/kg body wt at 0.04 ml/min) throughout the experiment. A total of three urine samples were collected at 30-min intervals. Blood samples were obtained at the beginning and end of the experiment. After the clearance study, the kidneys were flushed with saline and fixed in methacarn solution for immunohistochemical analysis. We determined inulin, in plasma and urine, using the anthrone method.
Analysis of blood and urine. The volume of each 24-h urine sample was measured gravimetrically. Urine samples were centrifuged in aliquots to remove suspended material, and the supernatants were analyzed. We measured urinary and plasma osmolality using a freezing-point osmometer (3D3; Advanced Instruments, Norwood, MA). We used flame photometry to measure serum and urinary levels of sodium and potassium, whereas we used kinetic techniques to measure serum levels of creatinine and urinary levels of urea. We measured serum Li levels using an ion-selective electrode. homogenates were centrifuged at low speed (2,000 g) for 15 min at 4°C to remove nuclei and cell debris. The supernatants were then spun at 100,000 g for 1 h at 4°C (70 Ti rotor; Beckman Coulter, Fullerton, CA), producing pellets containing membrane fractions enriched with plasma membranes and intracellular vesicles. The pellets were suspended in the same isolation solution. We also quantified AQP2 in plasma membrane and intracellular vesicle fractions prepared from the medulla. We prepared membrane vesicles using a modification of the standard method described above for membrane fractions. Using the Teflon pestle glass homogenizer, we homogenized medulla samples in the same isolation solution described above. The homogenates were centrifuged as above, and the supernatants were collected. Fractions enriched for plasma membranes (low-speed) and for intracellular vesicles (high-speed) were prepared by centrifugation of the supernatants at 17,000 g for 30 min and 200,000 g for 1 h, respectively. The pellets were suspended in the same isolation solution.
Preparation of renal samples for eNOS, iNOS, and PDE5 expression assays. We used the Teflon pestle glass homogenizer to homogenize kidney samples or medulla samples in ice-cold isolation solution (200 mM mannitol, 80 mM HEPES, 41 mM KOH, pH 7.5) containing the protease inhibitor cocktail. The homogenates were centrifuged at low speed (3,000 g) for 15 min at 4°C to remove nuclei and cell debris. The pellets were suspended in isolation solution with protease inhibitors. Protein concentrations were determined by the Bradford assay method (Bio-Rad Protein Assay kit; Bio-Rad Laboratories, Hercules, CA).
Electrophoresis and immunoblotting. Membrane fractions and kidney samples were run on 12.5% polyacrylamide minigels (for AQP2), 10% polyacrylamide minigels (for ␣-ENaC, ␤-ENaC, ␥-ENaC, NHE3, UT-A1, PDE5, and eNOS), or 8% polyacrylamide minigels (for NKCC2 and iNOS). After transfer by electroelution to nitrocellulose membranes (PolyScreen, PVDF Transfer; Life Science Products, Boston, MA), blots were blocked with 5% milk and 0.1% Tween 20 in PBS or TBS (for eNOS and PDE5) for 1 h. Blots were then incubated overnight with an anti-AQP2 antibody (1:2,000), NKCC2 antibody (0.12 g/ml), ␣-ENaC antibody (1:500), ␤-ENaC antibody (1:500), and ␥-ENaC antibody (1:500), NHE3 antibody (1:500), UT-A1 antibody (1:500), PDE5 antibody (1:500), eNOS antibody (1:2,000), and iNOS antibody (1:1,000). The labeling was visualized with a horseradish peroxidase-conjugated secondary antibody (antirabbit IgG, diluted 1:2,000, anti-goat IgG, diluted 1:10,000, or antimouse IgG diluted 1:2,000; Sigma) using the enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech, Piscataway, NJ).
Quantification of renal levels of AQP2, UT-A1, PDE5, sodium transporters, eNOS, and iNOS.
We scanned ECL films using Image Master VDS software (Pharmacia Biotech, Uppsala, Sweden) and performed quantitative analysis of antibodies using densitometry, normalizing the bands to actin expression.
Immunohistochemistry. For AQP2 and UT-A1 immunostaining, samples were processed in 4-m paraffin sections. After deparaffinization, endogenous peroxidase activity was blocked with 0.3% H 2O2 in water for 10 min at room temperature (16) . Sections were then subjected to incubation overnight at 4°C with an anti-AQP2 antibody (1:100) or anti-UT-A1 antibody (1:1,000). This was followed by incubation with biotinylated mouse anti-rat IgG for 30 min at room temperature. The reaction product was detected with the avidin-biotin-peroxidase complex (Vector Laboratories, Burlingame, CA). The color reaction was developed with 3,3-diaminobenzidine (Sigma), and the sections were counterstained with methyl green.
For all sections, negative controls consisted of replacing the primary antibody with equivalent concentrations of an irrelevant normal rabbit or normal goat IgG anti-mouse antibody. The sections were examined under light microscopy at a magnification of ϫ400.
Preparation of medullary collecting duct cell suspensions and determination of cGMP levels. We used freshly prepared suspensions of medullary collecting duct cells from the papillae of rats fed only standard rat chow for 4 wk and rats fed standard rat chow plus Li (40 mmol/kg food) for 4 wk. The papillae of each rat were excised from the kidneys, weighed, immediately placed into vials containing icecold solution (115.0 mM NaCl, 25.0 mM NaHCO 3, 10.0 mM CH3COONa, 5.0 mM KCl, 1.0 mM CaCl2, 1.2 mM MgSO4, 1.2 mM NaH2PO4, and 5.0 mM D-glucose), and finely minced. Subsequently, the suspensions were treated or not as follows: those from rats fed only standard rat chow for 4 wk were divided into a control-susp group (n ϭ 6) and a Sil-susp group (n ϭ 6; suspension incubated with 5 M Sil), whereas those from rats fed standard rat chow plus Li for 4 wk were divided into a Li-susp group (n ϭ 6) and a LiϩSil-susp group (n ϭ 6; suspension incubated with 5 M Sil). Incubations were for 45 min at 37°C in a shaking water bath, constantly bubbled with room air. The suspensions were then submitted to cGMP assay with the BioTrak kit (Amersham Pharmacia Biotech). This is a competition assay in which higher optical density (OD) values indicate less cyclic nucleotide in the original cell supernatant. In brief, the suspensions were purified in accordance with the manufacturer's instructions, after which they were lysed and centrifuged. The supernatant was then mixed with a rabbit anti-cGMP antibody. Aliquots were added to 96-well plates precoated with donkey anti-rabbit antibody, and cGMP-peroxidase conjugate was added to each well. After 1 h, the plates were washed, and a peroxidase substrate was added. The reaction was terminated with sulfuric acid. The ODs were read on a plate reader at 450 nm, and we used standard curves to compare ODs among samples. We performed all intracellular cGMP accumulation assays in triplicate. Statistical analysis. Quantitative data are expressed as means Ϯ SE. Differences among the means of multiple parameters were analyzed by ANOVA followed by the Student-Newman-Keuls test. Differences between parameters were analyzed by an unpaired t-test or by nonparametric methods (Mann-Whitney test). Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
Li induces NDI.
During the 4-wk study period, all animals received standard rat chow with a fixed concentration of sodium chloride and were given ad libitum access to tap water. Animals receiving Li developed NDI within 1 wk. At the end of week 1, urine output was significantly higher in Li and LiϩSil rats than in control and Sil rats (Fig. 1A) . In Li rats, NDI persisted throughout the study period ( Fig. 1A ; Table 1 ).
Sil markedly decreases urine output, free water clearance, and water intake in Li-treated rats. The Li rats gained less weight than did the control and Sil rats. However, this condition was ameliorated in LiϩSil rats (Table 1) . Urine output was significantly higher in Li rats than in LiϩSil rats ( Fig. 1A ; Table 1 ). Although urine output was 50% lower in LiϩSil rats than in Li rats, it was significantly higher in LiϩSil rats than in control and Sil rats. As expected, polyuria and water intake were significantly greater in Li rats than in control and LiϩSil rats ( Fig. 1A ; Table 1 ). In LiϩSil rats, free water clearance was significantly lower than it was in Li rats (Table 1 ; Fig. 1B) , although it remained significantly higher than that seen in the control and Sil rats, both of which presented free water reabsorption (Table 1; Fig. 1B) . The marked increase in urine output in Li rats was accompanied by decreased urinary osmolality, which was significantly lower in Li rats than in control and Sil rats. In LiϩSil rats, urinary osmolality increased from week 1 to week 4 (220 Ϯ 25 vs. 301 Ϯ 9.5 mosmol/kgH 2 O; P ϭ 0.013, paired t-test) and was significantly higher than that observed in Li rats (P ϭ 0.0002, Mann-Whitney test). However, the ANOVA revealed no statistical differences among groups in terms of urinary osmolality or food intake (Table 1) . Although urinary osmolality was higher in the LiϩSil-hi rats than in the LiϩSil rats (404 Ϯ 54.3 vs. 301 Ϯ 9.5 mosmol/ kgH 2 O), the difference was not statistically significant. Nor 
.4 ml/day).
Sil has no effect on renal Li clearance. To rule out any influence of Sil treatment on renal Li clearance, we measured serum Li levels, and we found no significant difference between Li rats and LiϩSil rats (Table 1) .
Sil has no effect on renal function. To address the question of whether the decrease in urine output observed in LiϩSil rats was due to a decrease in the glomerular filtration rate (GFR), we measured inulin clearance (the gold standard for determining GFR). We found no significant difference among the groups (control: 0.86 Ϯ 0.05; Sil: 0.69 Ϯ 0.03; Li: 0.94 Ϯ 0.04; and LiϩSil: 0.83 Ϯ 0.06 ml·min Ϫ1 ·100 g body wt Ϫ1 ). Serum creatinine levels were comparable among the groups.
Sil does not alter blood pressure or AVP levels in Li-treated rats. To assess whether the marked decreases in urine output and free water clearance, as well as the increase in urinary osmolality, observed in LiϩSil rats could be a result of Silinduced systemic vasodilatation, we measured MAP, RVR, RBF, and plasma AVP. As can be seen in Table 2 , there were no differences in terms of MAP. Although mean RVR was higher in the Li group than in any of the other groups, it normalized completely after Sil treatment. Mean RBF was Fig. 4 . Immunostaining for AQP2 in kidney medulla samples. Samples are from control (A), Li (B), LiϩSil (C), and Sil (D) rats (magnification ϫ40). Note that the AQP2 staining is less intense in the Li group sample than in the control and Sil group samples, as well as being more intense in the LiϩSil group sample than in the Li group sample. Also shown is immunostaining for AQP2 in kidney medulla samples from control (E), Li (F), LiϩSil (G), and Sil (H) rats (magnification ϫ100). Note that plasma membrane staining for AQP2 is less intense in the Li group sample than in the control and Sil group samples, as well as being more intense in the LiϩSil group sample than in the Li group sample. lower in Li rats than in control, LiϩSil, and Sil rats. Treatment with Sil partially restored RBF in Li rats. Mean plasma AVP levels did not differ among the groups.
Sil treatment does not alter serum or urinary levels of sodium and potassium but decreases urinary excretion of urea.
No significant differences were observed among the groups in terms of serum sodium, serum potassium, UVNa, or UVK. Although UVurea was higher in Li rats than in controls, it was significantly lower in LiϩSil rats than in Li rats (Table 1) .
Sil inhibits Li-induced downregulation of eNOS expression. Expression of eNOS was markedly lower in Li rats than in control and Sil rats (51 Ϯ 2.2 vs. 98.5 Ϯ 0.64 and 97.3 Ϯ 2.2%; P Ͻ 0.001). As can be seen in Fig. 2 , Sil treatment completely inhibited the downregulation of eNOS observed in Li rats (96.7 Ϯ 2.2 vs. 51 Ϯ 2.2%; P Ͻ 0.001). However, expression of iNOS was similar among the groups [control: 99 Ϯ 1.2, Sil: 97.4 Ϯ 1.5, Li: 90.3 Ϯ 3.9, and LiϩSil: 96.4 Ϯ 1.0%; not significant (NS)].
Treatment with the Li-Sil combination increases AQP2 expression. Figure 3 shows that AQP2 expression in crude membrane fractions was higher in LiϩSil rats than in Li rats (60 Ϯ 2.9 vs. 26.5 Ϯ 2.4%; P Ͻ 0.001), although it was lower in LiϩSil rats than in controls (60 Ϯ 2.9 vs. 106 Ϯ 2.8%; P Ͻ 0.001). In addition, AQP2 expression was higher in Sil rats than in controls (121 Ϯ 3.1 vs. 106 Ϯ 2.8%; P Ͻ 0.01). The difference between Sil rats and LiϩSil rats, in terms of AQP2 expression, was also significant (121 Ϯ 3.1 vs. 60 Ϯ 2.9%; P Ͻ 0.001). We also evaluated AQP2 expression in intracellular vesicles and plasma membrane fractions. As shown in Table 3 , plasma membrane AQP2 expression was higher in LiϩSil rats than in Li rats, although it was lower in LiϩSil rats than in controls, whereas it was higher in Sil rats than in controls. In the vesicles, AQP2 expression was comparable among Li, control, and LiϩSil rats. In the Sil group, AQP2 expression was higher, although not significantly so, compared with the other groups. There was also increased AQP2 expression in the apical plasma membrane, confirming that Sil induced transfer of AQP2 from intracellular vesicles to the plasma membrane (trafficking), as evidenced by the immunohistochemistry findings. Figure 4 shows representative sections of the medulla from rats in the Li and LiϩSil rats, probed to reveal the presence of AQP2, compared with those from control and Sil rats. In Sil rats, AQP2 was abundantly expressed, whereas it was barely detectable in Li rats. However, at week 4, the intensity of staining was greater in the sections from LiϩSil rats than in those from Li rats.
Treatment with Li alone or with the Li-Sil combination increases NKCC2 expression. Figure 5 shows that NKCC2 expression was comparable in Li rats and LiϩSil rats (151 Ϯ 4.3 and 163 Ϯ 3.3%; NS). Expression of NKCC2 was significantly higher in Li and LiϩSil rats than in control and Sil rats (163 Ϯ 3.3 and 151 Ϯ 4.3 vs. 100 Ϯ 0.88 and 93 Ϯ 3.3%, respectively; P Ͻ 0.001 for both). In Sil rats, NKCC2 expression did not differ significantly from that observed for the controls.
Sil reverses Li-induced downregulation of UT-A1. In LiϩSil rats, UT-A1 expression was higher than that seen in Li rats (92 Ϯ 4.0 vs. 50.2 Ϯ 3.3%; P Ͻ 0.001), and UT-A1 expression was comparable to that observed in controls (99.7 Ϯ 0.3%; NS), although different from that observed in Sil rats (108.3 Ϯ 4.7%; P Ͻ 0.05). There was no significant difference between Sil and control rats in terms of UT-A1 expression (Fig. 6) . Figure 7 demonstrates UT-A1 immunohistochemical staining of sections from control, Li, LiϩSil, and Sil rats. Consistent with the immunoblotting results, immunostaining for UT-A1 was markedly more intense in LiϩSil rats than in Li rats.
Sil does not reverse Li-induced changes in renal cortex abundance of NHE3. Semiquantitative immunoblotting revealed that renal cortex expression of NHE3 was significantly higher in Li-treated rats than in controls (134 Ϯ 5.5 vs. 99.3 Ϯ 0.7%; P Ͻ 0.001). In addition, NHE3 expression was higher in Li rats than in Sil rats (134 Ϯ 5.5 vs. 98 Ϯ 4.2%; P Ͻ 0.001), although there was no significant difference between LiϩSil rats and Li rats (138 Ϯ 1.4 vs. 134 Ϯ 5.5%; NS). However, NHE3 expression was significantly higher in LiϩSil rats than in the control and Sil rats (P Ͻ 0.001), although there was no significant difference between Sil and control rats (98 Ϯ 4.2 vs. 99.3 Ϯ 0.7%; NS).
Sil reverses Li-induced downregulation of ␥-ENaC. Neither Li alone nor the Li-Sil combination has any effect on renal cortex abundance of ␣-ENaC or ␤-ENaC. In Li rats, ␣-ENaC expression in the renal cortex remained stable (105 Ϯ 2.7%) and was comparable to that observed for control, Sil, and LiϩSil rats (99.3 Ϯ 0.67, 102.3 Ϯ 3.8, and 105 Ϯ 3.2%, respectively; NS, Fig. 8A ). We also evaluated ␤-ENaC and ␥-ENaC protein expression in the renal cortex. Abundance of ␤-ENaC was unaffected across the groups (control: 99.3 Ϯ 0. . Also shown is immunostaining for UT-A1 in kidney medulla samples from control (E), Li (F), LiϩSil (G), and Sil (H) rats (magnification ϫ100). Note that plasma membrane staining for UT-A1 is less intense in the Li group sample than in the control and Sil group samples, as well as being more intense in the LiϩSil group sample than in the Li group sample. for all). There were no significant differences among the control, Sil, and LiϩSil groups in terms of ␥-ENaC expression (Fig. 8C) .
PDE5 is expressed in the renal medulla. Expression of PDE5 in the renal medulla was comparable among the groups (control: 100 Ϯ 2.2, Sil: 105 Ϯ 8.5, Li: 91.4 Ϯ 5.2, and LiϩSil: 96 Ϯ 1.3%; NS, Fig. 9) . Each of the two subunits of PDE5 possesses a catalytic domain and a regulatory domain, the former being the target of PDE5 inhibitors. It should be borne in mind that we measured only the protein abundance of PDE5 (i.e., PDE5 activity was not measured).
Sil increases cGMP levels in medullary collecting duct cell suspensions. Investigating the effect that incubation with Sil had on intracellular cGMP levels in medullary collecting duct cell suspensions, we found that the mean cGMP level (expressed in fmol/g of papilla) was higher in the LiϩSil-susp group than in the control-susp group and Li-susp group (6,402 Ϯ 1,162 vs. 1,790 Ϯ 262 and 1,890 Ϯ 302, respectively; P Ͻ 0.001 for both). Although not significantly different from the LiϩSil-susp group value, the mean cGMP level observed for the Sil-susp group (5,012 Ϯ 699) differed significantly from the control-susp group value (P Ͻ 0.01). In addition, the mean cGMP level was significantly higher in the Sil-susp group than in the Li-susp group (P Ͻ 0.01, Fig. 10 ).
DISCUSSION
Chronic Li treatment is known to be a major cause of NDI (20, 23, 31) , and downregulation of AQP2 has been associated with the development of severe polyuria (20, 23, 31) . Here, we have demonstrated that, in rats with Li-induced NDI, chronic Sil treatment upregulates expression of AQP2 and UT-A1.
In the basolateral membrane of collecting duct principal cells, AVP binds to the AVP type 2 receptors (6, 19, 27, 28) . Acting through the GTP-binding protein Gs, the interaction between AVP and the AVP type 2 receptor activates adenylyl cyclase, accelerating the production of cAMP by ATP (6, 19, 28, 38) . Subsequently, cAMP binds to the regulatory subunit of PKA, resulting in dissociation of the regulatory subunit from the catalytic subunit. This activates the catalytic subunit, phosphorylating AQP2 (9, 27, 28) , which is then translocated from intracellular vesicles to the plasma membrane (6, 9, 27, 28) . It has been shown that Li inhibits AVP-induced adenylyl cyclase activity and cAMP levels in the medullary collecting duct (8) , and this inhibition is the likely cause of the reduced expression of AVP-regulated AQP2 (8) . However, it has also been shown that Li inhibits such activity by reducing AQP2 mRNA (likely through decreased gene transcription), and that Li-induced AQP2 degradation and NDI occur independently of principal cell adenylyl cyclase activity (3, 22) . In addition, Li alters neither AVP-stimulated cAMP production nor PKA-dependent phosphorylation of AQP2 and cAMP-responsive elementbinding protein (22) .
In 2000, Bouley et al. (4) identified another pathway of AQP2 plasma membrane insertion. The authors described a cAMP-independent, cGMP-dependent pathway for AQP2 membrane insertion in renal epithelial cells. This suggests that AQP2 phosphorylation at S256 is required for cGMP-stimulated AQP2 trafficking, although it remains unknown whether the final phosphorylation step is through PKA or through cGMP-activated PKG (4, 5, 10) . In our study, we were unable to measure S256-phosphorylated AQP2. Although we demonstrated that plasma membrane AQP2 expression was higher in LiϩSil rats than in Li rats, we were also unable to determine whether the final phosphorylation step is through PKA or PKG.
It has also been shown that AQP2 accumulates in the plasma membrane of collecting duct principal cells and LLC-AQP2 cells upon exposure to the selective PDE5 inhibitor Sil, which also inhibits cGMP degradation (5) . In cultured cells, this occurs with no detectable increase in cAMP (4). It is unknown whether the Sil effect is due to increased AQP2 exocytosis, decreased AQP2 endocytosis, or both (4). In our study, Sil administration in Li-treated rats decreased urine output and increased urinary osmolality, as well as increasing AQP2 expression. Therefore, Sil treatment might represent a novel therapeutic approach for patients with Li-induced NDI. The exact mechanism by which Sil increases AQP abundance and trafficking in Li treated rats remains unknown.
We also investigated the question of whether UT-A1 expression is affected by Sil treatment in Li-induced NDI. Chronic Li administration is a model of NDI in which UT-A1 expression decreases (2, 18) , as confirmed in the present study. Acting through PKA, AVP increases the UT-A1 phosphorylation in inner medullary collecting duct cell suspensions (1, 35, 36, 37, 42) . It has been demonstrated that UT-A1 sensitivity to AVP-induced phosphorylation is lower in Li-treated rats (18) . In the present study, Sil treatment significantly increased UT-A1 expression in the medulla, despite ongoing Li therapy. The increased collecting duct water reabsorption after Sil treatment would increase urea concentration in the inner medullary collecting duct, where urea permeability is quite high (35) , which would explain the increased UT-A1 expression in the LiϩSil rats in the present study. We also demonstrated that UVurea was lower in LiϩSil rats than in Li rats. We hypothesized that the Sil-induced increase in UT-A1 expression in the inner medullary collecting tubule in the LiϩSil rats results in greater permeability to urea, causing urea to diffuse into the interstitium, thus increasing interstitial osmolality. However, in contrast to our data, it has been shown that atrial natriuretic factor inhibits the vasopressin-dependent increase in urea permeability in the inner medullary collecting ducts, an effect that is mediated by cGMP (25, 30) . Further studies are needed to identify the exact mechanism by which Sil increases UT-A1 expression in Li-treated rats.
Chronic Li treatment has been associated with a significant increase in UVNa in rats (20, 23) , especially in a model of high-dose Li treatment (60 mmol/kg food) (20) . Even in rat models of low-dose Li treatment (40 mmol/kg food), UVNa has been shown to increase, albeit to a lesser degree than in the high-dose model (20) . In Li and LiϩSil rats, expression of NHE3, the major apical sodium transporter in the proximal tubule, was increased, as was expression of NKCC2, the major apical sodium transporter in the thick ascending limb. Expression of ␣-and ␤-ENaC was not affected by Li treatment, with or without Sil. In Li-treated rats, there was a decrease in ␥-ENaC protein expression, which was completely normalized by Sil treatment. In our model, as expected, there was no statistically significant difference among the groups in terms of UVNa. However, although not significant, there was a 50% decrease in UVNa in the LiϩSil group. Further studies, in a high-dose model with a fixed sodium intake, are needed to elucidate the role that Sil plays in sodium channel dysregulation.
The levels of cGMP were increased in the Sil and LiϩSil groups. However, in the Sil group rats, urine output, UT-A1 expression, and expression of sodium transporters did not differ from the values obtained for the rats in the control group (in which there was no increase in cGMP levels). One interpretation of these results is that the lack of any apparent Sil-induced effect on urine output, UT-A1 expression, or sodium transporter expression in the Sil group is related not to PDE5 inhibition in the collecting ducts but rather to systemic PDE5 inhibition that affects a circulating factor and thus modifies protein expression in the collecting duct, independently of cGMP levels. However, it should be borne in mind that the animals were studied after having received Sil for 3 wk, which translates to chronic treatment. In addition, when Sil is given to normal rats, the mechanisms at work might be quite different from those activated when Sil is given to animals under treatment with Li. Furthermore, the increased cGMP levels in the medullary collecting duct tubules after Sil administration was an in vitro finding and should therefore be interpreted with caution. Body weight, which is a measure of extracellular volume expansion, was not significantly higher in the Sil group than in the other groups; nor did the Sil group rats show any decrease in urine output or increase in urinary osmolality, although AQP2 expression was higher in this group. We hypothesized that these differences (no increase in body weight; no increase in urine output, no increase in urinary osmolality) were due to the fact that our animals received Sil for 3 wk, with the following consequences: extracellular volume expansion and altered sodium balance (although not significant, there was a tendency toward higher UVNa and lower serum levels of sodium compared with the control group). In response to the extracellular volume expansion, sodium is excreted in urine (the mechanism of sodium balance). Hence, the characteristic findings in a steady state are a discrete increase in UVNa and a discrete decrease in serum levels of sodium. It is likely that (after 3 wk of treatment with Sil) our animals had reached a steady state in terms of sodium and water balance.
In Li-treated rats, RVR was increased but was completely normalized by Sil treatment. We also demonstrated decreased eNOS expression in Li-treated rats. We hypothesized that this decrease was responsible for the increase in RVR in those rats. The phenotypes of mice lacking all three NO synthases are polyuria, polydipsia, and renal unresponsiveness to AVP, characteristics consistent with NDI (40) . In our study, Sil treatment also completely restored eNOS expression in Li-treated rats.
To date, there have been no studies demonstrating decreased eNOS expression in this model of Li-induced NDI. However, some studies have reported that the erectile dysfunction seen in patients receiving Li can be attributed to Li blockade of the NO pathway, as demonstrated in endothelium-mediated relaxation of rat corpus cavernosum (34) . Chronic Li treatment might impair the NO-mediated neurogenic relaxation of rat corpus cavernosum, which could be prevented by the NO precursor L-arginine (34) . Although Sil has been used in the treatment of erectile dysfunction (24) , it is currently also used for the management of pulmonary hypertension (11, 14) . Rostaing et al. (33) showed that, in kidney transplant recipients, GFR (inulin clearance) increases within 120 min after Sil administration. Rodriguez-Iturbe et al. (32) demonstrated that early treatment with Sil slows the progression of renal damage.
In conclusion, using Sil to treat Li-induced NDI reduces polyuria, increases urinary osmolality, and decreases free water clearance via upregulation of renal AQP2 and UT-A1, as well as normalizing RVR and eNOS expression. A therapeutic approach that includes Sil could have significant clinical implications in patients suffering from Li-induced NDI. 
